The Priority Review

The stream · Daily digest

The stream: Friday, November 13, 2026

18 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Approvals · 9

  1. FDA approves first drug to treat adults with primary membranous nephropathy

    The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.

    Source: FDA approval notification, November 13, 2026

  2. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by single-agent durvalumab as adjuvant therapy after radical cystectomy for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted under priority review and six weeks ahead of the FDA goal date.

    Source: FDA approval notification, November 13, 2026

  3. EMA recommends approval of seven new medicines at CHMP meeting

    The Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Aumseqa, Baxfendy, Zybrivo, Garzulys, Donrafylix, Fondaparinux sodium Evumed, and Ruxolitinib Krka. The recommendations cover treatments for non-small cell lung cancer, hypertension, non-squamous non-small cell lung cancer, diabetes, venous thromboembolism, and myelofibrosis, among others.

    Source: EMA news release, November 13, 2026

  4. CHMP adopts positive opinion on Zybrivo for non-squamous NSCLC

    On 12 November 2026 the CHMP recommended granting a marketing authorization for Zybrivo, a sintilimab-based therapy, for first-line treatment of adult non-squamous non-small cell lung cancer. The recommendation follows a randomised, multicentre, double-blind, placebo-controlled study showing improved progression-free survival when sintilimab is combined with chemotherapy.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

  5. CHMP recommends marketing authorization for Ruxolitinib Krka

    On 12 November 2026 the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for Ruxolitinib Krka, intended for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease. The generic will be available as 5 mg, 10 mg, 15 mg and 20 mg tablets.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

  6. CHMP adopts positive opinion on Fondaparinux sodium Evumed

    On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a marketing authorization for Fondaparinux sodium Evumed, a generic of Arixtra. The product is intended for prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery, immobilised patients, and for treatment of unstable angina, myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

  7. CHMP adopts positive opinion on Donrafylix

    On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Donrafylix, a biosimilar insulin aspart intended for the treatment of diabetes mellitus. The applicant is Kuraci BV and Donrafylix will be available as a 100 units/ml solution for injection.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

  8. CHMP adopts positive opinion on Baxfendy

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

  9. CHMP adopts positive opinion on Aumseqa

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorization for Aumseqa, a 55 mg film-coated tablet intended for first-line treatment of adult patients with advanced NSCLC harbouring EGFR exon 19 deletions or L858R mutations, and for treatment of EGFR T790M mutation-positive NSCLC. The applicant for the medicinal product is SFL Pharmaceuticals Deutschland GmbH.

    Source: EMA medicine page (CHMP opinion), November 13, 2026

Clinical trials · 8

  1. Novatek registers Phase 2/3 trial of NP-101 in GEP-NECs

    The study, led by Novatek Pharmaceuticals, plans to enroll an estimate of 381 participants to evaluate the safety and efficacy of NP-101 combined with Nivolumab and Ipilimumab versus placebo in refractory advanced and metastatic gastroenteropancreatic neuroendocrine carcinomas. It is planned to begin in January 2027 and reach primary completion in December 2029.

    Source: ClinicalTrials.gov registry record, November 13, 2026

  2. AstraZeneca registers Phase 3 trial of Symbicort Aerosphere in children

    The study plans to enroll 216 participants aged 4 to <12 years and start on October 30, 2026. It plans to compare BFF MDI 80/4.8 μg 2 actuations BID to BD MDI 80 μg 2 actuations BID over 6 weeks to assess lung function and safety.

    Source: ClinicalTrials.gov registry record, November 13, 2026

  3. RemeGen registers Phase IIIb trial of RC28-E Injection in DME and wAMD

    The study, led by RemeGen Co., Ltd., plans to enroll 350 participants and has a planned start date of October 30, 2026. It aims to evaluate the safety profile and explore the efficacy of RC28-E in participants with diabetic macular edema and wet age-related macular degeneration.

    Source: ClinicalTrials.gov registry record, November 13, 2026

  4. RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer

    The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.

    Source: ClinicalTrials.gov registry record, November 13, 2026

  5. Janssen posts results of Phase 3 seltorexant trial in major depressive disorder with insomnia

    The study enrolled 757 participants and began on September 15, 2020, with primary completion on October 3, 2023. It compared seltorexant 20 mg to quetiapine XR as adjunctive therapy to antidepressants in adults and elderly patients with major depressive disorder with insomnia symptoms who had responded inadequately to antidepressant therapy.

    Source: ClinicalTrials.gov results record, November 13, 2026

  6. AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma

    The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.

    Source: ClinicalTrials.gov results record, November 13, 2026

  7. Harmony Biosciences posts results of Phase 3 pitolisant study in idiopathic hypersomnia

    Results for the open-label study were first posted on ClinicalTrials.gov on November 13, 2026. The completed study enrolled 119 participants and assessed the long-term safety and effectiveness of pitolisant after the double-blind randomized withdrawal phase of HBS-101-CL-010.

    Source: ClinicalTrials.gov results record, November 13, 2026

Regulation · 1

  1. CMS announces optional hold harmless period for Medicaid work requirement

    CMS said the optional hold harmless period runs through June 30, 2027, giving states a transition period to modernize systems and improve the beneficiary experience. States that implement the hold harmless period will assess whether individuals meet the work requirement or are excluded from it, but they will not deny applications or disenroll otherwise eligible individuals solely for failure to meet the requirement.

    Source: CMS press release, November 13, 2026